Table 2a
HLA type Allele Healthy control (n=20705) Breast cancer patients
(n=173)
SYFPEITHI score Recognition site BIMAS Recognition site
A *24:02 35.9 29.3 12 YQDTILWKDIFHKNNQLALT  
  *02:01 11.5 11.8 20 YQDTILWKDIFHKNNQLALT 2.8 YQDTILWKDIFHKNNQLALT
  *02:06* 9.2 16.8 0    
  *11:01 9.1 8.7 17 YQDTILWKDIFHKNNQLALT 2.4 YQDTILWKDIFHKNNQLALT
  *31:01* 8.6 20.5 0   3.6 YQDTILWKDIFHKNNQLALT
  *26:01 7.5 4 0    
B *52:01 11.1 26   13.2 YQDTILWKDIFHKNNQLALT
  *51:01 9.0 6.6 14 YQDTILWKDIFHKNNQLALT 4.4 YQDTILWKDIFHKNNQLALT
  *35:01* 8.2 17.9   1 YQDTILWKDIFHKNNQLALT
  *40:02 7.8 7.1 0    
  *15:01 7.8 8.4 11 YQDTILWKDIFHKNNQLALT  
  *54:01 7.6 13.9    
             
  *44:03 6.5 6 0   15 YQDTILWKDIFHKNNQLALT
  *07:02 5.6 3.3 13 YQDTILWKDIFHKNNQLALT  
  *40:01 5.3 5.3 14 YQDTILWKDIFHKNNQLALT  
  *46:01 4.8 7    
  *40:06 4.6 4.7      
  *39:01 3.4 3.3 24 YQDTILWKDIFHKNNQLALT 27 YQDTILWKDIFHKNNQLALT
  *48:01 2.8 4.4    
 
 
 
  *39:02 0.3 0.6 11 YQDTILWKDIFHKNNQLALT  
Table 2b
AB Allele Healthy control (n=20705) Breast cancer patients (n=173) Breast cancer patients (n=173) Recognition site IEDB Analysis Recognition site
DRB1 *09:01 14.1 35.9 0      
*04:05* 13.7 8.4 0      
  *15:02 10.5 10.8 0   4.64 YQDTILWKDIFHKNNQLALT
  *08:03 8.6 7.9 0      
  *15:01 7.7 8.7 20 YQDTILWKDIFHKNNQLALT   YQDTILWKDIFHKNNQLALT
  *01:01 5.8 3.7 18 YQDTILWKDIFHKNNQLALT   YQDTILWKDIFHKNNQLALT
  *13:02 5.7 5.5 0   2.4  
  *08:02 4.2 3.7 0   2.76  
  *12:01* 3.7 7.5 0      
  *11:01 2.7 3.7 24 YQDTILWKDIFHKNNQLALT 4.33 YQDTILWKDIFHKNNQLALT
Table 2: HLA alleles of the patients and healthy donors with predicted affinity scores
a)The percentages of the HLA types of both healthy donors and breast cancer patients in Japan are shown in parallel with the SYFPEITHI, BIMAS, and IEDB analyses scores.
b)Recognized sequences are shown as underlined text. (―) means the allele and the peptide affinity could not be simulated by the algorithm.